NASDAQ:BIOC Biocept Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.90 -0.06 (-6.40%) (As of 06/24/2022 06:55 PM ET) Add Compare Share Today's Range$0.90▼$1.0050-Day Range$0.90▼$1.8152-Week Range$0.90▼$4.53Volume275,700 shsAverage Volume126,929 shsMarket Capitalization$15.23 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOC Stock Forecast (MarketRank)Overall MarketRank™1.68 out of 5 starsMedical Sector915th out of 1,411 stocksMedical Laboratories Industry22nd out of 31 stocksAnalyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingBiocept has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Biocept has a forecasted upside of 344.4% from its current price of $0.90.Amount of Analyst CoverageBiocept has received no research coverage in the past 90 days. Previous Next 4.3 Community Rank Outperform VotesBiocept has received 359 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiocept has received 196 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiocept has received 64.68% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote “Outperform” if you believe BIOC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiocept does not currently pay a dividend.Dividend GrowthBiocept does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biocept insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.39% of the stock of Biocept is held by insiders.Percentage Held by InstitutionsOnly 13.52% of the stock of Biocept is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biocept are expected to decrease in the coming year, from ($0.66) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biocept is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biocept is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiocept has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biocept (NASDAQ:BIOC)Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.Read More BIOC Stock News HeadlinesJune 23, 2022 | uk.finance.yahoo.comProactive news headlines including ACME Lithium, Mindset Pharma, HighGold Mining, Usha Resources and Zynerba Pharmaceuticals - Yahoo Finance UKJune 22, 2022 | streetinsider.comProactive news headlines including ACME Lithium, Mindset Pharma, HighGold Mining, Usha Resources and Zynerba Pharmaceuticals - StreetInsider.comJune 22, 2022 | proactiveinvestors.comBiocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial - Proactive Investors USAJune 22, 2022 | finance.yahoo.comPlus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM TrialJune 22, 2022 | finance.yahoo.comThe global liquid biopsy market is predicted to surpass US$ 11 Billion by 2030 - Yahoo FinanceJune 22, 2022 | americanbankingnews.comBiocept (NASDAQ:BIOC) Given a $4.00 Price Target by Maxim Group AnalystsJune 20, 2022 | finance.yahoo.comPrecision Diagnostics Market Size, $168Bn by 2028, 13.3% CAGR Lead by Genetic Tests Segment, Global Forecast & Analysis by The Insight Partners - Yahoo FinanceJune 19, 2022 | americanbankingnews.comBiocept, Inc. (NASDAQ:BIOC) Short Interest UpdateJune 16, 2022 | finance.yahoo.comDemand for Global Breast Biopsy Market Size & Share to Surpass USD 1,109.35 Million by 2028, Exhibit a CAGR of 7.3% | Breast Biopsy Industry Trends, Growth, Value, Analysis & Forecast Report by Facts & Factors - Yahoo FinanceJune 13, 2022 | streetinsider.comForm 8-K BIOCEPT INC For: Jun 10 - StreetInsider.comJune 12, 2022 | americanbankingnews.comBiocept (NASDAQ:BIOC) Now Covered by StockNews.comJune 7, 2022 | benzinga.comBiocept to Hold Business Strategy Conference Call Today - Benzinga - BenzingaJune 7, 2022 | finance.yahoo.comBiocept to Hold Business Strategy Conference Call TodaySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees104Year FoundedN/ACompany Calendar Last Earnings5/23/2022Today6/27/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+344.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2.82 million Net Margins-11.26% Pretax Margin-12.72% Return on Equity-19.99% Return on Assets-12.16% Debt Debt-to-Equity Ratio0.03 Current Ratio3.38 Quick Ratio3.15 Sales & Book Value Annual Sales$61.25 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.40Miscellaneous Outstanding Shares16,923,000Free Float16,688,000Market Cap$15.23 million OptionableOptionable Beta0.66 Biocept Frequently Asked Questions Should I buy or sell Biocept stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biocept stock. View analyst ratings for Biocept or view top-rated stocks. What is Biocept's stock price forecast for 2022? 2 Wall Street research analysts have issued 12-month target prices for Biocept's stock. Their BIOC stock forecasts range from $4.00 to $4.00. On average, they predict Biocept's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price. View analysts' price targets for Biocept or view top-rated stocks among Wall Street analysts. How has Biocept's stock performed in 2022? Biocept's stock was trading at $3.62 at the beginning of 2022. Since then, BIOC stock has decreased by 75.1% and is now trading at $0.90. View the best growth stocks for 2022 here. Are investors shorting Biocept? Biocept saw a drop in short interest in May. As of May 31st, there was short interest totaling 243,600 shares, a drop of 16.2% from the May 15th total of 290,700 shares. Based on an average daily trading volume, of 103,900 shares, the short-interest ratio is presently 2.3 days. View Biocept's Short Interest. When is Biocept's next earnings date? Biocept is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Biocept. How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, May, 23rd. The medical research company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The medical research company had revenue of $19.95 million for the quarter, compared to analysts' expectations of $6.99 million. Biocept had a negative net margin of 11.26% and a negative trailing twelve-month return on equity of 19.99%. View Biocept's earnings history. When did Biocept's stock split? How did Biocept's stock split work? Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split. Who are Biocept's key executives? Biocept's management team includes the following people: Mr. Samuel D. Riccitelli, Interim Pres, CEO & Chairman (Age 63, Pay $67.24k)Mr. Antonino Morales, Interim CFO & Director (Age 66, Pay $20.76k)Dr. Michael C. Dugan M.D., Sr. VP, Chief Medical Officer & Medical Director (Age 59, Pay $413.31k)Dr. Soon Kap Hahn Ph.D., FounderDr. Philippe J. Marchand Ph.D., Chief Operating Officer (Age 59)Mr. Pavel Tsinberg, Director of Technology Devel.Mr. Darrell Taylor Esq., Sr. VP, Chief Legal Officer & Chief Compliance Officer (Age 57)Mr. David S. Moskowitz R.Ph., MBA, VP of Strategy & Corp. CommunicationsMr. Michael Terry, Sr. VP of Corp. Devel. (Age 67)Antonio Paternostro, VP of Sales What is Michael Nall's approval rating as Biocept's CEO? 1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Biocept's key competitors? Some companies that are related to Biocept include Sera Prognostics (SERA), Centogene (CNTG), Psychemedics (PMD), OpGen (OPGN), Vyant Bio (VYNT), PharmChem (PCHM), American Shared Hospital Services (AMS), CannLabs (CANL), CBA Florida (CBAI), Aclarion (ACON), Zicix (ZICX), AnPac Bio-Medical Science (ANPC), First Choice Healthcare Solutions (FCHS), PotNetwork (POTN) and Aeon Global Health (AGHC). View all of BIOC's competitors. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST). What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." Who are Biocept's major shareholders? Biocept's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.69%), Acadian Asset Management LLC (0.16%), Taylor & Morgan Wealth Management LLC (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Biocept stock include David F Hale and David F Hale. View institutional ownership trends for Biocept. Which institutional investors are selling Biocept stock? BIOC stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View insider buying and selling activity for Biocept or view top insider-selling stocks. Which institutional investors are buying Biocept stock? BIOC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Taylor & Morgan Wealth Management LLC, and Group One Trading L.P.. View insider buying and selling activity for Biocept or or view top insider-buying stocks. How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $0.90. How much money does Biocept make? Biocept (NASDAQ:BIOC) has a market capitalization of $15.23 million and generates $61.25 million in revenue each year. The medical research company earns $-2.82 million in net income (profit) each year or ($0.45) on an earnings per share basis. How many employees does Biocept have? Biocept employs 104 workers across the globe. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for Biocept is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225. This page (NASDAQ:BIOC) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here